Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53 by Morris,  G. F. et al.
Proc. Natl. Acad. Sci. USA
Vol. 93, pp. 895-899, January 1996
Cell Biology
Transcriptional activation of the human proliferating-cell nuclear
antigen promoter by p53
GILBERT F. MORRIS*, JAMES R. BISCHOFFt, AND MICHAEL B. MATHEWS
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724
Communicated by James D. Watson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, October 2, 1995 (received for review April 3, 1995)
ABSTRACT Proliferating-cell nuclear antigen (PCNA) is
a DNA damage-inducible protein that performs an essential
function in DNA replication and repair as an auxiliary factor
for DNA polymerases 6 and e. Examination of the human
PCNA promoter DNA sequence revealed a site with homology
to the consensus DNA sequence bound by p53. PCNA pro-
moter fragments with this site intact bound p53 in vitro and
were transcriptionally activated by wild-type p53 in transient
expression assays in SAOS-2 cells. The resident p53-binding
site could be functionally substituted by a previously described
p53-binding site from the ribosomal gene cluster. A plasmid
expressing a mutated version of p53 derived from a patient
with Li-Fraumeni syndrome failed to activate the PCNA
promoter in the cotransfection assay. In different cell types,
activation of the PCNA promoter by the p53-binding sequence
correlated with the status of p53. Activation of the PCNA
promoter by wild-type p53 depends upon the level of p53
expression. This concentration dependence and cell type
specificity reconciles the observations presented here with
prior results indicating that wild-type p53 represses the PCNA
promoter. These findings provide a mechanism whereby p53
modulates activation of PCNA expression as a cellular re-
sponse to DNA damage.
In human cancers, frequent mutations in the gene encoding
the p53 tumor suppressor protein highlight the importance of
p53 in the control of cell growth and suppression of neoplastic
transformation (1-4). Wild-type p53 is a nuclear phosphopro-
tein that can activate or repress transcription (2, 3, 5). In
accord with its role in the regulation of cell proliferation,
wild-type p53 induces growth arrest and suppresses transfor-
mation by a variety of cellular and viral oncogenes (3, 4). In
contrast, mutant alleles of p53 cooperate with activated ras in
cotransfection assays to transform primary cells (3, 4). Agents
that damage cellular DNA cause an increase in cellular p53
levels, and elevated p53 levels correlate with cell cycle arrest
or with apoptosis (5-9). Cells lacking wild-type p53 lost the
ability to arrest after DNA damage (8). Mice lacking the p53
gene develop normally but are prone to an early onset of
cancer (10). Moreover, thymocytes from mice with an ablated
p53 gene are resistant to induction of apoptosis by irradiation
(11). These observations and others (for review, see refs. 1-4,
12, and 13) suggest that p53 regulates DNA replication, DNA
repair, and programmed cell death; however, the mechanisms
by which p53 elicits these important cellular functions remain
unknown.
The preponderance of data suggests that the regulatory
activities of p53 are related to its function as a transcription
factor (1-4). Activation of transcription by wild-type p53
correlates with its binding to a specific DNA sequence (2, 3).
The consensus DNA sequence specific for p53 binding consists
of two copies of the inverted repeat sequence [RRRC(A/
T)(A/T)GYYY] separated by 0-13 nucleotides (2, 3). A
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number of genes that contain a p53-binding site are transcrip-
tionally activated in vivo and in vitro by p53 (2, 3, 5). The DNA
binding and transcriptional activation properties of p53 may be
regulated by its posttranslational modifications or by interac-
tions of p53 with other cellular or viral proteins (3). Tran-
scriptional repression by wild-type p53 in vivo and in vitro
appears to be mediated [with some exceptions (14, 15)]
through a more general mechanism that involves DNA ele-
ments of the basal promoter (3, 16). Wild-type p53 represses
transcription from minimal promoters containing a TATA
motif, whereas initiator-directed transcription from minimal
promoters lacking a TATA box resists repression by p53 (16).
The TATA-mediated mechanism for p53 repression of tran-
scription is consistent with the observation that p53 can bind
directly to the TATA-binding protein of the transcription
factor TFIID complex (17-19). Although TFIID is also re-
quired for transcription initiation of TATA-less promoters (20,
21), the transcription initiation pathways of promoters with
and without a TATA motif may differ sufficiently to provide
the means for distinct responses to p53 (22).
Relevant target genes for the transcriptional regulatory
functions of p53 must be identified to fully understand how p53
controls cell growth and suppresses neoplastic transformation.
The proliferating-cell nuclear antigen (PCNA), or DNA poly-
merase 6 auxiliary factor, is an essential DNA replication
protein (23) that is increased in abundance in proliferating
cells (24-26). Consistent with the role of PCNA in DNA
replication, its promoter is activated in HeLa cells by coex-
pression of the adenovirus ElA protein (27). Sequences 50
nucleotides upstream of the transcription initiation site with
homology to the consensus site bound by the activating
transcription factor mediate activation of the PCNA promoter
by ElA (27, 28). Mutant ElA proteins that fail to induce DNA
synthesis in quiescent cells also fail to activate the PCNA
promoter in HeLa cells (29).
PCNA is also required for DNA repair (30-33) and in this
capacity it is induced concomitantly with increasing p53 levels
in human skin cells exposed to ultraviolet radiation (34). The
DNA repair function of PCNA and its coexpression pattern
with p53 suggest that the PCNA promoter is a target for
transcriptional regulation by p53. Moreover, PCNA can be
found in a quaternary complex with cyclins, cyclin-dependent
kinases, and p21, a recently identified inhibitor of cyclin-
dependent kinases that is transcriptionally regulated by p53
(35, 36). p21 inhibits PCNA DNA replication activity by direct
binding (37) and permits PCNA DNA repair functions (32).
We have identified a sequence in the PCNA promoter that
is homologous to the DNA consensus sequence bound by p53.
This sequence bound p53 in vitro and mediated activation of
the PCNA promoter by wild-type p53 upon coexpression in
p53-deficient SOAS-2 cells. In contrast, a PCNA promoter
Abbreviations: PCNA, proliferating-cell nuclear antigen; CAT, chlor-
amphenicol acetyltransferase; RGC, ribosomal gene cluster.
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construct with the p53-binding site deleted was repressed by
coexpression of wild-type p53. Replacement of the p53-
binding site with a heterologous p53 binding site restored
activation by wild-type p53. Expression of an oncogenic mu-
tant form of p53 failed to activate expression from any of the
PCNA promoter-chloramphenicol acetyltransferase (CAT)
constructs in the coexpression assay. The p53-binding se-
quence activated the PCNA promoter in cells containing, but
not in cells lacking, wild-type p53. Activation of the PCNA
promoter by wild-type p53 depended upon the level of p53
expression. These observations suggest a cellular response to
DNA damage (9, 34, 38) whereby p53 activates expression of
PCNA.
MATERIALS AND METHODS
Plasmids. The PCNA CAT construct containing nucleotides
-249 to +62 was described (39) and was referred to as +60.
The PCNA-CAT construct containing nucleotides -213 to
+62 was prepared by digesting with Eag I and cloning the
desired restriction fragment between the Xho I and HindlIl
sites of pBACAT. The sequence of the upstream border of
-213 PCNA-CAT from the common Xho I site is ctc-
gaggGGCCGGG (with PCNA promoter sequences in upper-
case type). As described for the -249 to +62 PCNA-CAT
construct, the downstream border was formed at the Nru I site
(+62, previously +60; ref. 39) in the PCNA promoter with the
addition of a HindlIl linker. The RGC213 PCNA-CAT con-
struct was prepared by inserting wild-type p53-binding se-
quences from the ribosomal gene cluster (RGC) into a Xho I
site upstream of the -213 PCNA-CAT construct as shown
below (with the RGC sequence underlined).
ctcgagTTTTGCCTGGACTTAGCCTGGCCTTG
Gel Mobility Shift Assays. Epitope-tagged wild-type human
p53 (42, 43) was purified from baculovirus-infected insect cells
by immunoaffinity methods as described (44). The binding
reaction was as follows: 1 ,ug of purified p53 prepared was
incubated with bovine serum albumin (22 ,ug/ml)/0.2 mM
dithiothreitol/20 mM Tris, pH 8.0/50 mM NaCl/5% glycerol/
0.02 Nonidet P-40/poly(dWdC) (6.67 ,ug/ml)/104 cpm of 32p-
labeled DNA in a final volume of 15 ,l. In some experiments,
1 ,ul of PAb421 ascites fluid (Oncogene Science) was added.
After 30 min at 22°C, the binding reaction mixtures were
resolved on a 5% polyacrylamide gel containing 0.5x TBE.
The gel was electrophoresed for 1 h at 200 V and dried for
autoradiography. Double-stranded oligonucleotide probes for
the gel shift assays were end-labeled with [32P]dCTP and the
Klenow fragment of DNA polymerase I (45).
RESULTS
Examination of the PCNA promoter between nucleotides
-217 and -236 revealed that 18 out of 20 nucleotides match
the p53-binding consensus.
p53 consensus sequence RRRCWWGYYYRRRCWWGYYY
111111111111111111
PCNA promoter sequence GAACAAGTCCGGGCATATGT
- 217 - 236
R is a purine, Y is a pyrimidine, andW is A or T. To determine









Cells. SAOS-2 cells were obtained from American Type
Culture Collection (ATCC). Monolayer cultures were grown in
McCoy's medium with 15% (vol/vol) fetal bovine serum,
penicillin (100 ,ug/ml), and streptomycin (100 ,ug/ml). HeLa
cells were obtained from American Type Culture Collection.
Monolayer cultures were grown in Dulbecco's modified Ea-
gle's medium (DMEM), 10% fetal bovine serum, and peni-
cillin and streptomycin as above. CREF cells were obtained
from P. Fisher (Columbia University). Monolayer cultures
were grown in DMEM, 5% fetal bovine serum, and penicillin
and streptomycin as above. Baby rat kidney (BRK) cells were
prepared and grown as described (40).
Transfection Assays. Transfection assays of all cell types
were as described (39) with the exception of SAOS-2 cells. For
SAOS-2, cells at 50-60% confluence in 6-cm dishes were
transfected by the calcium phosphate method (39). Each
transfection mixture contained 10 ,ug of the reporter plasmid
and 0.5,g of the p53 expression plasmid-human wild-type or
mutant p53 [pC53-SN3 (41) and pCMVp53E258K, respective-
ly]-driven by the human cytomegalovirus virus immediate-
early promoter. In the absence of the p53-expressing plasmid
in the transfection, 0.5 ,tg of pCMV12S.FS, a plasmid con-
taining the human cytomegalovirus promoter directing expres-
sion of a nonfunctional ElA mRNA (27), was included as
control. After 3.5 h, the DNA precipitate was removed and the
cells were exposed to 15% (vol/vol) glycerol for 1 min followed
by the addition of fresh medium. Cells were harvested 48 h
after transfection. A 100-/lA freeze-thaw extract was prepared
from each plate of transfected cells and 50 Al of each extract
was assayed for CAT activity as described (27). One CAT unit
is defined as 1% conversion of chloramphenicol to its acety-
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FIG. 1. Gel mobility shift assays with oligonucleotides correspond-
ing to the PCNA promoter. Double-stranded oligonucleotides corre-
sponding to the wild-type PCNA promoter sequence (PCNA), a
mutated version designed to disrupt p53 binding (MUTANT), or the
p53 binding sequence from the RGC were employed in gel mobility
shift assays with purified wild-type human p53. The wild-type PCNA
oligonucleotide was incubated without protein (lane 1), with purified
human p53 (lane 2), or with purified p53 and monoclonal antibody
PAb421 (lane 3). Similar analyses were performed with the mutated
PCNA sequence (lanes 4-6) and the RGC motif (lanes 6-9). Band A
is a specific complex formed with the wild-type human p53 and the
PCNA promoter sequence in lanes 2 and 3. Band B is a slower
migrFating complex formed upon addition of monoclonal antibody
specific for p53.
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assays were performed with a double-stranded oligonucleotide
corresponding to the PCNA promoter sequence (Fig. 1).
Wild-type human p53 purified from insect cells infected with
a recombinant baculovirus produced a specific complex (band
A, lane 2). A slower-migrating complex (band B) appeared upon
addition of a monoclonal antibody, PAb421, specific for p53 to
the gel shift assay (Fig. 1, lane 3). Similar complexes were formed
when the PCNA promoter oligonucleotide was replaced by an
oligonucleotide corresponding to the p53-binding site from the
RGC (46). No such complexes were formed with a mutant PCNA
sequence harboring changes in the conserved nucleotides C4 and
G7 that were expected (47) to disrupt p53 binding (Fig. 1, lanes
5 and 6). These data indicate that sequences in the PCNA
promoter bind wild-type human p53 specifically; consideration of
the relative band intensities (compare lanes 2 and 3 with lanes 8
and 9) suggests that the affinity of p53 for the PCNA sequence
is greater than that for the RGC sequence.
Several studies have explored the regulation of human
PCNA expression by wild-type p53 with various results (16,
48-51). Since DNA sequences that bind p53 mediate tran-
scriptional activation by the protein (2), one might expect that
binding of p53 to the PCNA p53-binding site would activate
transcription from the PCNA promoter. To test this predic-
tion, we first determined whether wild-type p53 affects tran-
scription from the PCNA promoter in SAOS-2 cells. This
human osteosarcoma cell line is devoid of p53 as a result of a
gene deletion (41). SAOS-2 cells were employed in two
previous reports indicating that the PCNA promoter is re-
pressed by coexpression of wild-type p53 (48, 49). A cotrans-
fected plasmid encoding wild-type human p53 stimulated
PCNA-CAT expression approximately 4.5-fold (Fig. 2B) from
a reporter plasmid containing PCNA promoter sequences
from nucleotides -1265 to +62 directing CAT gene expression
(-1265 PCNA-CAT, Fig. 2A). The stimulation was greatest at
low amounts (0.25 and 0.5 tg) and essentially disappeared with
higher amounts of the p53 expression vector. A similar re-
sponse was obtained with a shorter form of the promoter
(-249 PCNA-CAT; Fig. 2A), which retains the p53-binding
site (Fig. 2C). Further truncation of the promoter, giving the
-213 PCNA-CAT construct (Fig. 2A), removes this site and
abrogated the stimulation entirely (Fig. 2C). Comparable
results were also obtained in HeLa cells that are also p53-
deficient (data not shown).
The results shown in Fig. 2 suggested that p53 stimulates the
PCNA promoter in a concentration-dependent fashion and
implicated the p53-binding site in the response. The data of
Table 1 support these inferences. To confirm that the p53-
binding site is required, a previously defined heterologous
p53-binding site from the RGC (46) was inserted upstream of
position -213 in place of the natural p53-binding site, to
produce the RGC213 reporter construct (Fig. 2A). This sub-
stitution restored transcriptional activation by wild-type p53 to
the -213 promoter (Table 1) even though the homology
between the p53-binding site in RGC and the p53-binding site
in the PCNA promoter is only 8 of 20 nucleotides. To confirm
that p53 mediated the stimulation, we assayed a transdominant
mutant of p53 with a Glu -> Lys change at amino acid 258 (52,
53). Cotransfection with a plasmid expressing this mutant p53
had little effect on any of the PCNA-CAT promoter constructs
(Table 1). We conclude that sequences between positions
-249 and -213 within the PCNA promoter that bind p53 in
vitro mediate activation by wild-type p53 in vivo.
To explore the generality of this finding, we assayed the two
PCNA-CAT constructs containing (-249) and lacking (-213)
the p53-binding site (Fig. 2A) in three different cell lines that
display variable activity of wild-type p53 (Table 2). As before
(Table 1) in SAOS-2 cells, which lack p53, removal of the p53-
binding site activated PCNA-CAT expression by about 75%
(Table 2). In HeLa cells, p53 is bound to the human papillo-
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FIG. 2. Low levels of wild-type p53 expression activate the PCNA
promoter via the PCNA p53-binding site. (A) Diagram of PCNA-CAT
constructs. Cloned human PCNA promoter fragments were fused to
the CAT reporter gene in pBACAT. (B) The -1265 to +62 PCNA-
CAT construct (10 jig) was cotransfected with increasing amounts of
the wild-type p53-expressing plasmid (pC53-SN3) into SAOS-2 cells.
The CAT activity obtained in the absence of the p53-expressing
plasmid was normalized to one. The results shown are from a single
experiment performed in duplicate. (C) PCNA-CAT constructs (10jig) with (-249 to +62 PCNA-CAT) and without (-213 to +62
PCNA-CAT) the p53-binding site were cotransfected with increasing
amounts of the wild-type p53-expressing plasmid into SAOS-2 cells.
The CAT activity obtained with each PCNA-CAT construct in the
absence of the p53-expressing plasmid was normalized to one. The
results shown are from a single transfection performed in duplicate.
Similar results were obtained upon repetition of the experiment.
CAT expression from the -213 construct was reduced by
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construct Control + wt p53 p53 n
-249 12.7 ± 5.6 31.5 ± 11.2 11.2 ± 4.1 5
-213 24.1 ± 7.6 6.2 ± 1.4 19.3 ± 5.7 4
RGC213 24.6 ± 1.9 94.1 ± 22.9 18.6 ± 4.5 3
Values for CAT expression are the average values for CAT activity
in relative units with standard deviation for the indicated number of
experiments (n). Each experiment was performed in duplicate.
cells (Table 2), indicating that removal of the p53-binding site
in the PCNA promoter exerted little effect on PCNA-CAT
activity in these cells. In contrast to these relatively small
effects, in primary baby rat kidney (BRK) cell cultures removal
of the p53-binding site from the PCNA promoter reduced
PCNA-CAT expression by about 4-fold (Table 2). This ob-
servation supports the view that the p53 binding site in the
PCNA promoter mediates transcriptional activation in cells
expressing wild-type p53. Removal of the p53 binding site also
reduced PCNA-CAT expression by about 3-fold in CREF cells
(Table 2). The status of p53 in CREF cells appears to be wild
type by two criteria: an authentic p53 binding site can activate
transcription in CREF cells (see below) and CREF cells are a
clonal derivative of rat embryo fibroblasts (55) that undergo
wild-type p53-mediated apoptosis upon expression of the
adenovirus ElA 243R protein (56, 57). Thus, the PCNA
promoter sequences that bind p53 in vitro mediate activation
of the promoter in cells with wild-type p53 expression (CREF
and BRK cells) and these sequences do not activate the
promoter in cells lacking wild-type p53 expression (HeLa and
SAOS-2 cells).
If the sequence from nucleotides -236 to -217 in the PCNA
promoter constitutes a p53-binding site that mediates cell-
type-specific transcriptional activation by wild-type p53, intro-
duction of a heterologous p53-binding site should restore
activity to the - 213 PCNA-CAT construct in the same
cell-type-specific manner. To test this prediction the RGC213
construct (Fig. 2A) was also assayed in the same four cell types
(Table 2). In BRK and CREF cells, the heterologous p53
binding site restored promoter activity in the RGC213 con-
struct to levels comparable to those obtained with the -249
construct in these two cell types (Table 2). In SAOS-2 and
HeLa cells, however, insertion of the heterologous p53 binding
site had no effect on, or slightly stimulated, the promoter
activity of the -213 construct (Table 2). We conclude from
these data that the PCNA promoter sequence can be func-
tionally replaced by a previously defined wild-type p53-binding
sequence from the RGC in cells with wild-type p53 expression
(BRK and CREF cells). Moreover, these observations suggest
Table 2. Activation of PCNA-CAT expression by PCNA
sequences between -249 and -213 depends on the
status of p53 in a given cell type
CAT expression
Cell type p53 status -249 -213 RGC213 n
HeLa Bound by 1.0 0.66 ± 0.17 1.54 ± 0.5 3
HPV E6
SAOS-2 Absent 1.0 1.72 ± 0.96 2.35 ± 0.86 3
BRK wt 1.0 0.24 ± 0.08 1.32 ± 0.26 3
CREF wt? 1.0 0.34 ± 0.07 1.18 ± 0.39 6
CAT values are normalized to those obtained with the -249
construct with CMV12S.FS in the different cell types. The average
relative CAT activity with standard deviation of the indicated PCNA-
CAT construct is shown with the indicated number of experiments (n).
Each experiment was assayed in duplicate. HPV, human papilloma-
virus.
that the principal function of these sequences in the PCNA
promoter correlates with p53 binding. In the absence of
functional p53 (HeLa and SAOS-2 cells), deletion of the
PCNA p53-binding sequence or its replacement with the RGC
sequence has minimal effect. On the other hand, this site is
responsible for stimulation of PCNA promoter expression in
cells that contain functional p53.
DISCUSSION
Our data indicate that wild-type p53 binds to a site between
nucleotides - 217 and - 236 in the human PCNA promoter and
activates expression. These observations are compatible with
the functions of p53, as an inducer of DNA repair (6, 8, 33),
and PCNA, as a DNA repair protein (30-32). Thus, activation
of the PCNA promoter by p53 would constitute a cellular
response to DNA damage and is consistent with previous
observations indicating that DNA damaging agents activate
expression of both p53 and PCNA (G.F.M., unpublished
results and refs. 6, 9, 34, and 38).
p53 has multiple and far-reaching effects on cells and its
effects on the human PCNA promoter can vary from cell type
to cell type and with p53 concentration. The results shown here
provide a basis for understanding the various effects reported
(16, 48-51). In a study of the human glioblastoma cell line
GM47.23, which is transformed with a gene expressing wild-
type p53 from a steroid inducible promoter, induction of p53
expression reduced PCNA mRNA levels (51). However, it was
not clear whether this reduction was a direct effect of wild-type
p53 or an indirect consequence of p53-induced growth arrest,
and the step in PCNA mRNA biosynthesis that was inhibited
was not identified. In the human cervical epithelial cell line
C33A, coexpression of wild-type p53 had no effect on human
PCNA-CAT expression (16). Additional studies showed that
wild-type p53 repressed expression from a human PCNA-
CAT reporter in HeLa and Vero cells (50). These results were
expanded in subsequent experiments demonstrating a 2- to 4-fold
reduction in PCNA-CAT expression by wild-type p53 in
SAOS-2 cells (48, 49), the p53-minus cell line employed in
the experiments described herein. Mutant p53 transactivated
PCNA-CAT expression in HeLa and SAOS-2 cells through a
sequence with homology to an activating transcription factor
binding site in the PCNA promoter (48,49). The mouse PCNA
promoter is also repressed by coexpression of wild-type p53
(58), but no sequence that mediates transcriptional repression
of the PCNA promoter by p53 has been identified (16, 50, 58).
On the other hand, we show here that transcriptional
activation of the PCNA promoter by wild-type p53 in SAOS-2
cells is mediated by sequences that bind p53 in vitro. Both the
-249 and the longer -1265 PCNA-CAT constructs were
activated in a dose-dependent fashion (Fig. 2). These cells were
chosen as an experimental model because the absence of p53
expression in SAOS-2 cells precludes complicated interactions
of the transiently expressed wild-type protein with endogenous
wild-type or mutant p53. The data shown in Fig. 2 indicate a
possible explanation for the discordant reports of p53 regula-
tion of PCNA expression; i.e., the level of p53 protein affects
the response of the PCNA promoter. Furthermore, this con-
centration-dependent response of the PCNA promoter to p53
raises the possibility of differential cellular responses to DNA
damage in which p53 can either activate or repress PCNA
expression. Such transcriptional regulation of a DNA repair
protein by p53 would be consistent with its functions as an
activator of DNA repair (e.g., in the activation of the PCNA
promoter) and an inducer of apoptosis (e.g., in the repression
of the PCNA promoter). However, it is not likely that p53 acts
alone to regulate the PCNA promoter, independent of other
cellular factors. For example, p53 also activates expression of
MDM-2, which can, in turn, antagonize the transcriptional
effects of p53 (59). The binding affinity of p53 to DNA can also
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be modulated (60, 61). So the concentration of p53 is likely to
be only one of many variables in the regulation of PCNA
expression.
The demonstration that PCNA, a DNA replication and
repair protein, is regulated by p53 provides an ideal model
system for understanding the functions of p53 as a regulator of
DNA synthesis and repair processes. In addition, the recent
finding that PCNA is associated with cell cycle regulatory
proteins (62-64) suggests a mechanism whereby cellular
PCNA levels are linked to cell cycle progression. Since cyclin-
dependent kinases can also alter p53 binding affinities for
some DNA sequences (60), it will be interesting to determine
whether p53 binding to PCNA promoter sequences is altered
by PCNA-associated kinases.
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